Dr. Manfred Beilharz, Co-Investigator in Australian Influenza Phase 2 Clinical Trial, Interviewed on 6PR Nightline Program Regarding Interferon and Influenza

AMARILLO, TX--(Marketwire - August 17, 2009) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR)
today announced that Dr. Manfred Beilharz, Chairman of the Department of
Microbiology and Immunology, School of Biomedical, Biomolecular and
Chemical Sciences at the University of Western Australia, was recently
interviewed by Graham Mabury on 6PR Nightline, a radio program in
Australia. Dr. Beilharz is a co-investigator of the ongoing Phase 2,
200-subject clinical trial that is testing the efficacy of ABI's oral
interferon alpha in preventing influenza and winter colds.

Dr. Beilharz discusses the development history and mechanism of action of
oral interferon as well as the ongoing Phase 2 clinical trial in Perth,
Australia in which 200 healthy volunteers are taking oral interferon
lozenges provided by Amarillo Biosciences, Inc. or a matching placebo once
a day for 16 weeks as a prevention for winter colds and influenza. The
interview can be heard at:
http://www.amarbio.com/index.php?option=com_content&view=article&id=85&Itemid=100013

About Amarillo Biosciences

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global
partnership with the Hayashibara Group, which also holds 7% of Amarillo
Biosciences shares and has provided over $18 million in loans, grants and
equity investments. The Company's primary focus is extensive and ongoing
R&D into the use of low-dose, orally administered interferon as a treatment
for a variety of conditions, including influenza, hepatitis C, chronic
cough, and opportunistic infections in patients who are HIV positive. In
its 25-year history, the Company has invested nearly $40 million to
establish oral interferon as a therapeutic agent. The majority of those
funds were invested in clinical trials in an effort to achieve FDA approval
for interferon. Additional information is available on the web site at
http://www.amarbio.com/.

Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon or the Company's other product
candidates and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission. In particular, see
"Item 1. Description of Business" and "Item 7A. Qualitative and
Quantitative Disclosures About Market Risk" of the Company's Form 10-K for
the fiscal year ended December 31, 2008.